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Abstract: Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the
intestinal mucosa and unknown etiology. In this review, we identified three main eras in the IBD
history. Between the 19th and the 20th century, the primary task had been the definition of the
diagnostic criteria in order to differentiate the new entity from intestinal tuberculosis. In the 20th
century, an intense and prolific therapeutic research prevailed, culminating in the introduction of
biological drugs in the clinical setting. Since the beginning of the 21st century, traditional definition
criteria have been challenged by holistic criteria in an effort to seek a still unattained cure. Centuries
of worldwide efforts on IBD etiology and therapy search have culminated in this novel strategy.
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1. Introduction
In the last 70 years, the scientific community has become progressively aware of a trans-organ
pattern of inflammation where non-specific mild (indolent) markers of inflammation have replaced
the classically known organ-specific stigmata fully manifesting as redness, swelling, and pain [1].
The apparent driving forces of this phenomenon were listed as: (a) switch from an agriculture-based
lifestyle towards an industrial and post-industrial mode, (b) privilege of product quantity over quality,
resorting to automated work and frequent night-shifts, and (c) changing fiber-based diets for industrial
fast-food [2].
As a barrier organ, the digestive tube was among the first structures to be hit by such changes,
translating into the epidemic-like entities of ulcerative colitis (UC) and Crohn’s disease (CD), the two
main types of inflammatory bowel diseases (IBD) [3]. The attitudes of investigators towards the novel
challenges posed by the spreading of IBD (mostly but not exclusively in the Western regions) can be
subdivided into three temporal phases: the definition of diagnostic criteria, the search for therapy and,
ultimately, an attempt to a holistic vision. Here, we address these three temporal phases of the IBD,
and discuss the history of this disease and related evolutionary findings across centuries.
2. Methods
Articles published in English regarding the history of IBD diagnosis, the evolution of therapy, and
the role of IBD in the context of systemic inflammation were identified through MEDLINE, SCOPUS,
ISI-Web of Knowledge, and EMBASE searches using the terms “ulcerative colitis”, “Crohn’s disease”,
“inflammatory bowel disease”, “history”, “diagnosis”, “therapy”, and “interactome”. The final search
date was 30 May, 2019. Reference lists from published articles were also employed. The titles of these
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publications and their abstracts were analyzed in order to eliminate duplicates and irrelevant articles.
Two authors (G.C.A. and D.G.R.) independently reviewed the literature search results and selected
the relevant studies. The full text of all retrieved papers was also assessed to determine whether the
inclusion criteria were met.
3. Results and Discussion
3.1. The History of the Search for Inflammatory Bowel Diseases (IBD) Etiology
The first report of a deadly bowel disease which corresponds to what is now known as UC was
done by Matthew Baillie in 1793 [4]. Later, the name “ulcerative colitis” was coined by Samuel Wilks in
1859 in London [5] in a patient with bowel disease which, today, would probably be labeled as CD [6].
In 1907, John Percy Lockhart-Mummery used, for the first time, an electrically illuminated endoscope,
designed to reach the sigmoid colon, and reported a malignancy in 7 out of 36 UC patients [7].
Thereafter, transmissible agents [8] were eagerly sought to explain the breakout of IBD, this bias
being justified, among other observations, by case-series reporting inter-spouse transmission of
CD [9]. No doubt, Mycobacterium tuberculosis was the most searched for years. The presence of
granulomatous lesions in CD, and the surprising, though erratic, response of cohorts of CD patients to
anti-tuberculosis chemotherapeutics justified these conjectures [10]. In 1920, Jacob Arnold Bargen of
the Mayo Clinic studied in depth the role of Diplostreptococci as causative agents of UC. He repeatedly
found Diplostreptococci in rectal ulcers of UC patients [11] and could induce colitis in rabbits inoculated
with this bacterium [12]. Other microorganisms supposedly implicated as etiologic agents of IBD
were Bacteroides fragilis, Bacteroides necrophorum, Helicobacter hepaticus or pylori, Listeria, Pseudomonas
maltophilia, pathogenic Escherichia coli, Chlamydia, Shigella, Coxsakie A, B, Wolinella, Norwalk virus, Polio
virus, Reovirus, herpes virus, Paramyxovirus, and Influenze B, as well as the loss of helminths [13].
In 1947, Meyer and Gellhorn proposed that UC was caused by a reduction of the mucus layer
above the enterocytes, due to an increase in the lysozyme enzymes, with consequent contact of the
luminal bacteria with intestinal mucosa resorting to an inflammatory reaction [14]. Neurosis, food,
and pollen allergy [15] were further hypothesized as UC triggers. Moreover, allergy to cow milk was
considered as a cause of UC onset [16].
For around twenty years, the “hygiene hypothesis” argued that the increased incidence of allergic
and dysimmune diseases could be a consequence of the decreased incidence of infectious diseases (e.g.,
tuberculosis) in the Western world, mirroring an improved hygiene: the immune system, no longer
committed to defense against infectious agents, would be allowed to face commensal microorganisms,
resulting in an inappropriate and prolonged inflammatory state [17].
UC has also been considered for many years as a psychosomatic disease [18], with the identification
of a specific psychologic profile predisposing to the onset of UC, a tenet heralded ever since the 1930’s.
Unfortunately, most of the studies included no control group, and relied on results to draw conclusions
while mixed entry criteria generated confusion [18].
The first paper to report an involvement of autoimmunity in the pathogenesis of UC was published
by Broberger and Perlmann [19]. In the absence of supporting evidence, this claim did not receive
further attention. The fundamental role of genetics as a contributing factor in IBD has become evident
when pioneering population studies confirmed the increased incidence in relatives (up to the third
degree) of the affected individuals [20]. Through genome-wide association studies (GWAS), more than
230 genes associated with an increased risk of developing IBD were discovered, most of which were
shared by both CD and UC [21]. Notably, most of these encode proteins involved in the response
to microorganisms.
In 1997, Roediger et al. highlighted the dietary intake of sulfur compounds as a causal factor of
UC [22]. In the last few years, the rising incidence of IBD in developing countries has been attributed
to the worldwide spread of a Western-style diet (rich in fats, sugars, and refined foods and poor in
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vegetables, fruits, whole wheat, and nuts), with the intestinal microbiome mediating proinflammatory
effects [23].
The human microbiota consists of a wide variety of microorganisms. Every human being
harbors between 10 trillion and 100 trillion microbial cells. The indigenous gastrointestinal (GI) tract
microflora has relevant effects on the anatomical, physiological, and immunological development of
the host. Understanding of human microbiota has evolved over the past years. Culture-independent
assays have shown that, although 98% of the GI microbiota is composed of four phyla of bacteria
(Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria), the majority are from either Firmicutes
or Bacteroidetes. Interest in this field has grown and intestinal microbiota and microbiome have become
a key topic of investigation in several GI diseases. In the quest for the cause of IBD, the involvement of
several bacterial species as well as a decrease in diversity of the intestinal microbiome (dysbiosis), with
a reduction of 25% in the bacterial species have been found [24].
3.1.1. The Role of Genetics in the Pathogenesis
Further information on IBD pathogenesis was obtained by genetic studies. More than 230 genetic
loci have been identified as associated with an increased risk of developing IBD. The majority of
IBD susceptibility genes are linked to pathways involved in immune–microbe interactions and
include: microbial detection, immune activation and suppression, and fucosylation of the mucosal
epithelium. Some of these genes encode for proteins involved in bacterial recognition, including the
interleukin (IL)-23 receptor (IL-23R), the autophagy-related protein 16-1 (ATG16L1) and the IL-10
receptor (IL-10R) [25].
The nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are a family
of evolutionarily conserved intracellular sensors that recognize a wide range of microbial- and
damage-associated signals during infection and inflammation. Upon activation, these innate immune
receptors can lead to nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) signaling
or inflammasome cascades [26]. NOD2 is a cytosolic pattern recognition receptor that senses muramyl
dipeptide (MDP), a component of peptidoglycan found in the cell wall of both Gram-positive and
Gram-negative bacteria [27]. Mutations are thought to result in “loss of function” and cause defective
bacterial sensing. Up to 40% of CD patients have at least one allele mutated in NOD2, while mutations
in both NOD2 alleles are found in 10% of these [28]. Upon activation, NOD2 signaling is mediated
by Rip2 kinase, which activates NF-κB and MAPK leading to increased immune gene expression
and inflammation. These observations suggest that innate immune responses to bacteria are a key
element in the pathogenesis of CD. Furthermore, patients with NOD2 mutations have reduced defensin
production and secretion by Paneth cells, increased T cell and humoral immune responses and,
probably, a loss of tolerance to the commensal gut microbiota [29]. NOD2 is also involved in other
cellular defense mechanisms, such as autophagy, in which MDP sensing by NOD2 induces recruitment
of the autophagy protein ATG16L1 to the bacterial entry site in the plasma membrane [30]. Indeed, the
CD-associated frameshift mutation of NOD2 fails to induce ATG16L1 recruitment and results in an
incomplete autophagosome formation.
3.1.2. Changes in Epidemiology and Implications for Pathogenesis
The epidemics-like pattern of IBD worldwide in the last 30 years, suggested that a single genetic
mutation cannot be the cause of the disease. It is estimated that currently >3 million individuals
have IBD in Europe, and 5 million worldwide. A time-trend analysis has shown that 75% of CD
studies and 60% of UC studies reported a statistically significant increasing incidence [31]. Rapid
industrialization and urbanity of wide areas in the Eastern World coincided with increasing incidence
and prevalence of IBD. Recent studies have reported an IBD incidence of 1.37 × 105 in Asia and of 3.4
× 105 in China [32]. These data indicate a rising trend, if compared with the traditional incidence of
0.60–3.44 × 105. As early as 2015, the reasons for this escalation were listed as life westernization, use
of appendectomy, milk formula feeding, and changing diets [33]. The incidence of pediatric IBD (CD)
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in the South Island of New Zealand has long been the matter of scrutiny. Data from a recent study [34]
have confirmed an epidemics-like behavior of CD in the area, with one of the highest incidence peaks
worldwide, probably caused by reduced bioavailability of vitamin D.
Sources of relevant information regarding IBD are studies of migration. In Canada, Eastern
families which adopted a Western lifestyle achieved an IBD incidence rate that closely matched those
of Canadian inhabitants; children seemed to be most sensitive to local injuring factors [35]. Cuban
exiles rejoining their families in Florida have been described to have a “North American” IBD risk.
Interestingly, the authors of the survey highlighted a progressive decrease of the lag time between
arrival to Florida and IBD onset [36]. We further hypothesized that a worsening anxious mood of the
migrants in response to the rapid changes of the social conditions in the USA, could be responsible for
this decrease [37]. Studies of IBD dynamics have so far raised more questions than answers, and it is
with genuine anticipation that we reappraised a few recent studies of urbanization of IBD patients,
emphasizing a role for microbiome changes. Transitioning from rural to metropolitan life, the switch
from fresh prevalently vegetarian food to elaborate meat recipes, and changes of feeding times due
to work shift, may have had a deep impact on microbiome, which did not keep pace with the rapid
changes [38].
3.1.3. Impact of Diet on Incidence and Course
Compared with healthy controls, CD patients have a lower vegetable and fruit intake, an increased
consumption of both processed low fiber bread (white bread), and high-sugar foods. When patients
with CD or UC were sub-grouped according to butyrate-acetoacetate Coenzyme A (CoA)-transferase
(BCoAT) gene content, patients with CD and high BCoAT gene concentration had a larger intake of nuts
than those with low BCoAT levels, whereas no dietary changes were found in patients with UC. When
dietary habits were compared, major significant differences between healthy controls and CD patients
with low BCoAT gene content were observed, with the latter showing reduced intake of certain foods
containing fibers such as vegetables, fruits, cereals, brown/whole meal bread, and nuts, and increased
intake of high-sugar foods and white bread. Accordingly, inflammation levels, disease-related changes
in microbiota composition, and decreased percentage of butyrate-producers were greater in patients
with CD having low BCoAT gene content than those with high BCoAT gene content. This suggests
that microbiota modulation, either achieved directly or promoted through the use of prebiotics, might
provide more consistent and efficient changes in butyrate concentrations in the gut compared to direct
butyrate administration [39].
3.2. The History of the Therapy for IBD
At the beginning of the 20th century, the treatment of colitis consisted of bed rest and colon
irrigation. For acute cases, an alkaline lotion, such as glycerin thymol 15%, or sodium bicarbonate or,
in case of severe ulcerations, hydrogen peroxide [6], was used. One of the first attempts at medical
treatment of UC was performed by Robert Fulton Weir in 1902 [40]. He performed an appendicostomy
to irrigate the colon with potassium permanganate, hypothesizing an infectious origin of the colitis.
For some years, several vaccines (for example against Diplostreptococci [15] or typhus [41]) were
evaluated, without success. The first effective medical therapy for UC came with the discovery of
sulfonamides in 1938, and with the use of the first antibiotics such as penicillin in 1946, revitalizing the
theory of an infectious cause of the disease [41].
Sulphasalazine, devised by Dr. Nana Svartz for the treatment of ‘infective polyarthritis’, was used
in the treatment of IBD for more than 70 years. Several controlled trials have shown that sulphasalazine
induced remissions in 50% to 75% of patients with active UC. Relapses were five times more likely in
untreated patients. Sulphasalazine is less effective in the case of CD, where it exerts only a transient
benefit in patients with active colonic disease and fails to prevent relapse or recurrence. Sulphasalazine
is absorbed from the small intestine, re-excreted in bile, and carried to the colon, where its azo bond is
split by bacteria to release sulphapyridine, which is absorbed and is responsible for most of the drug’s
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side effects, and 5-aminosalicylic acid (mesalazine), which is the active therapeutic moiety of the drug
and exerts a beneficial topical action on the colonic mucosa. Although side effects are common, these
are mainly reversible and not serious. Those related to high concentrations of sulphapyridine and to
poor acetylation of the drug include GI intolerance, malaise, headache, arthralgia, drug fever, effects
on red blood cells, and reversible male infertility. More serious, idiosyncratic side effects are skin
rashes, leukopenia, and agranulocytosis. Rarely, neurotoxicity, hepatotoxicity, polyarteritis, pulmonary
fibrosis, a lupus-like syndrome, and hemorrhagic colitis, surge. It is possible to desensitize most
patients with drug-induced skin rashes. A number of less toxic alternatives to sulphasalazine have been
devised. They either convey 5-aminosalicylic acid in a coated tablet to the colon or, when conjugated
to a non-toxic carrier, release the drug by bacterial cleavage [42].
The good response of UC to adrenocorticotropic hormone (ACTH) and adrenal corticosteroids in
the 1950s [43], in addition to changing the natural history of the disease, opened new horizons on its
immunological etiology. The 1940s witnessed men’s struggle for effective pharmaceuticals, somewhat
leaving aside the uncertainties over the true disease causes and emphasizing the inflammatory nature of
IBD. At that time, intravenous corticosteroids were shown to be clearly better than placebo in the control
of UC [44] and various aminosalicylic acid preparations proved effective as maintenance drugs [45].
Brooke et al. [46], pioneering the thiopurines, were unable to document an effect of these drugs on
the long-term disease course, yet they recommended the thiopurines [47] in hastening remission. On
the other hand, work at the New York Mt Sinai Hospital, did demonstrate a role of azathioprine in
achieving and solidly maintaining UC remission. The anecdotic use of 6-mercaptopurine for UC
has been reported as early as 1962 [46]. For roughly 30 years, the evidence of the effectiveness of
azathioprine/6-mercaptopurine for this disorder has been based on withdrawal experiments [48,49].
Focusing on CD, a pivotal double-blind study performed by Present et al. in 1980, demonstrated the
activity of 6-mercaptopurine in fistula closure and steroid sparing for patients with severe disease [50].
Finally, in the 1990s, the sequential use of the transplant drug cyclosporine [51], followed by
a long-term thiopurine, ameliorated the course of UC, a noteworthy data if one recalls that, in the
1950s, this disease was expected to be fatal for 30%–40% of those affected [52]. Ultimately, in the 1990s,
various formulations of monoclonal antibodies, hopefully capable of blocking those pro-inflammatory
cytokines (tumor necrosis factor (TNF), IL-23) that were chorally (non-selectively) addressed by drugs
of the cyclosporine generation, were made available to clinicians [53].
Early immunology research, conducted at the Kennedy Institute of Rheumatology in London,
demonstrated that TNF, among other cytokines and chemokines, was a primary driver of the
inflammatory responses observed in arthritic joints of animal models and in humans. Feldmann et al.
“dissected” the synovial tissue and components of the synovial fluid and described elevated expression
of TNF in both synovial tissue and synovial fluid of inflamed joints [54]. At Centocor, Knight et al.
developed the chimeric anti-TNF monoclonal antibody called infliximab [55]. The research team at the
Kennedy Institute of Rheumatology was able to treat, for the first time, rheumatoid arthritis patients
with infliximab in a randomized controlled trial [56].
Infliximab was also the first monoclonal antibody available for the treatment of IBD. In fact, it was
the first anti-TNF antibody to obtain market authorization for CD in the USA in 1998 and in the EU in
1999. With its 75% human component and a 25% murine component, this chimeric antibody binds
the pro-inflammatory protein TNF, both in its circulating and transmembrane form [57]. Infliximab
has been shown, since the first trials [58], to be effective in UC even in the most difficult situations of
steroid-refractoriness, matching the efficacy of cyclosporine [59]. Unfortunately, the murine component
of this hybrid construct has been found to lead, over time, to the production of a significant amount
of anti-infliximab antibodies. Thus, combination therapy with thiopurines is recommended in these
cases [60]. The standard induction schedule for infliximab, comprising three doses of 5 mg/kg given
at weeks 0, 2, and 6, has been derived from studies of CD and rheumatoid arthritis. However, these
diseases differ in their biology and inflammatory disease burden in patients with acute severe colitis.
A retrospective study by Gibson and colleagues showed that an accelerated infliximab induction
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schedule within four weeks reduced early colectomy rates at one month compared with standard
induction treatment over six weeks [61].
Adalimumab was the first fully humanized monoclonal antibody to be introduced in UC therapy,
yet the efficacy was hardly better than placebo in the induction of remission in moderately to severely
active forms [62]. Golimumab has been the latest anti-TNF antibody to be introduced for the treatment
of UC and is administered subcutaneously every 28 days. It has been shown to be significantly better
than placebo in inducing and maintaining remission in UC, without the need for combination therapy
with thiopurines [63,64].
The introduction of vedolizumab (which can be considered the “offspring” of natalizumab)
marked a breakthrough for the treatment of IBD, as it was the first biological drug selectively acting
on the gut. It blocks the α4β7 integrin, thus preventing leukocyte diapedesis from blood vessels
to the intestinal mucosa. Its advantages are a prolonged maintenance of remission and a low rate
of side effects (intestinal and upper respiratory tract infections). Despite being given intravenously,
vedolizumab confers a long-term response latency [65].
Recently, small molecules screening for an IBD cure has received much attention. Unlike biological
drugs (which are proteins), small molecules can be taken orally, and have refined bioavailability,
making blood levels determination unnecessary. For instance, tofacitinib is currently available on the
market. It is a non-selective inhibitor of the intracellular Janus kinase (JAK) 1/3 signaling cascade that
has given rapid efficacy results in UC either as a primary indication, or as a secondary resort anti-TNF
therapy. The enthusiasm induced by these results is, however, limited by a significant side effect rate
(in particular Herpes zoster manifestations, and pulmonary embolism) [66].
Naïve T lymphocytes play a key role in immune surveillance. Activation of these lymphocytes
occurs in secondary lymphoid organs, such as spleen, lymph nodes, and Peyer’s patches.
The chemoattractant sphingosine 1-phosphate (S1P) guides lymphocyte circulation through these
lymphoid organs in a gradient-dependent manner. Ozanimod is an oral S1P agonist that was previously
tested in patients with relapsing multiple sclerosis. In a double-blind, phase II randomized controlled
trial (RCT), the efficacy and safety of ozanimod in patients with moderate-to-severe UC was evaluated.
Clinical remission at week 8 was observed in 16% of patients receiving ozanimod 1 mg once a day (qd),
14% of patients receiving ozanimod 0.5 mg qd, and in 6% of patients receiving placebo. The difference
between the 1.0 mg and placebo groups was statistically significant. Furthermore, patients receiving
ozanimod 1 mg once qd achieved histologic remission more frequently than those receiving placebo
(22% versus 11%). Adverse events were similar in all groups. Phase III trials for CD (ClinicalTrials.gov
identifiers: NCT03 440372, NCT03440385, and NCT03464097) and UC (ClinicalTrials.gov identifiers:
NCT02435992 and NCT02531126) are ongoing [65]. The heterodimeric pro-inflammatory cytokines
IL-12 and IL-23 induce a TH1 and TH17 cell response, respectively. Ustekinumab is a monoclonal
antibody directed against the p40 subunit, therefore blocking the biologic activity of IL-12 and IL-23
simultaneously. The UNITI program recruited patients with CD and consisted of two phase III
induction RCT (UNITI-1 and UNITI-2) and one phase III maintenance RCT (IM-UNITI). Ustekinumab
was efficient both in the induction phase and in the maintenance phase in patients with CD. The safety
profile of this drug was acceptable. A phase III induction RCT in patients with moderate-to-severe
UC (UNIFI trial) met the primary endpoint of clinical remission at week 8. Patients were also given a
single dose of intravenous ustekinumab 130 mg, ustekinumab 6 mg per kilogram of body weight, or
placebo. After 8 weeks, 15.6%, 15.5%, and 5.3% of the patients were in clinical remission, respectively. A
significant decrease in fecal calprotectin was also observed in patients who received ustekinumab [67].
The increasing appreciation of the multiple causality of IBD has warranted the design of the
association of two biological drugs that act on different pathways. On this line, vedolizumab, with its
selective action at the level of the intestine, was proposed as the ideal pivot for this strategy: initial
reports from patients exposed to a combination of dual biological therapy have described a satisfactory
response rate in the presence of an acceptable toxicity [68].
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3.2.1. Relationship between Genetics and Response to Therapy
Comparison of genotypes between responders and non-responders revealed a significant difference
in the Fas ligand single-nucleotide polymorphism (SNP) rs763110 genotypes. Patients with a CC
genotype (compared to those with a TC or TT genotype) were more likely to be non-responders to
anti-TNF treatment (p = 0.016; odds ratio (OR) = 0.31). Abnormal regulation of apoptosis is one of
the mechanisms of CD pathogenesis. The extrinsic pathway is controlled through plasma membrane
receptors belonging to the TNF receptor superfamily that includes, among others, the Fas/Fas ligand
which has been implicated in IBD pathogenesis. Higher basal expression of the Fas ligand has been
significantly associated with the C allele compared with the T allele of this SNP [69]. Jürgens et al.
demonstrated that patients homozygous for IL-23 receptor SNPs, which increased the risk of IBD onset,
were more likely to respond to anti-TNF therapy compared to patients with IL-23 receptor SNPs that
had decreased risk [70].
A polymorphism of CCL2, a chemokine part of the IL-23 pathway that decreases T-cell migration
and impacts downstream on TNF-α levels, decreased the risk of durable response. It is possible
that polymorphisms in SNP decrease the effect of this protective chemokine. Suppressor of cytokine
Signaling 1 (SOCS1), a component of the IL-12 pathway, was associated with a higher likelihood
of durable response. PTPN22 (rs6679677) was associated with 2.26-fold increased odds of primary
non-response to anti-TNF therapy [71].
3.2.2. Attempt to Target Microbiota
The term “microbiome” [72] is commonly used to indicate any microbe population that indwells
the so-called barrier organs. Because of the huge number of bacteria, fungi, and bacteriophages in the
bowel, the multiple functions of the gut, and the involvement of its disorders into a huge series of
human diseases, the gut-associated microbiome has received renewed attention lately. We now know
that the gut microbiome components encompass 10 times the number of human cells in the body, and
the relevant genetic material is 100 times greater [73].
At gut level, a correct immune balance can be maintained only on the background of a “normal”
composition of the microbiome. Abnormal communication between gut microbial communities and the
mucosal immune system has been identified as the core defect that leads to chronic inflammation [74].
An alteration in the diversity and composition of the gut microbiome (dysbiosis), rather than the
presence of specific pathogens, likely plays a critical role in IBD pathogenesis. Several studies have
shown that there is a significant reduction in the diversity of stool microbiome of individuals with IBD:
25% fewer genes were detected in the fecal samples of IBD patients than in those of control patients.
The majority of IBD susceptibility genes (for example NOD2, ATG16L1, and IL-23R genes) are linked to
pathways involved in immune–microbe interactions [75].
Mesalazine inhibits the growth of Mycobacterium avium subspecies paratuberculosis, which has
been reported to be intimately linked to the etiology of CD in a dose-dependent manner in vitro.
Furthermore, it has been reported that mesalazine downregulates the expression of genes associated
with bacterial invasiveness and antibiotic resistance of Salmonella enterica serovar Typhimurium, which
could promote the onset of IBD after its infection. Furthermore, mesalazine inhibits the growth of
sulfate-reducing bacteria and suppresses sulfide production in IBD.
Anti-TNF-α antibody therapy has been reported to affect the gut microbiota. For instance,
the abundance of Faecalibacterium prausnitzii increased in responders during the induction of anti-TNF-α
antibody therapy. Another study reported that the relative number of Escherichia coli in CD significantly
decreased three months after the start of anti-TNF-α antibody therapy [76].
Interestingly, thiopurines were found to inhibit the growth of Mycobacterium avium subspecies
paratuberculosis in vitro [77]. Another study reported that thiopurine use significantly reduced the
bacterial diversity and richness in fecal samples in IBD, when compared to other drugs, including
anti-TNF-α antibodies, mesalazine, and corticosteroids [78].
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In a prospectively recruited cohort of patients with IBD initiating vedolizumab therapy, the
relationship between gut microbial taxonomic composition and function and response to vedolizumab
therapy was investigated. Eighty-five patients (42 with CD and 43 with UC) were included. Community
α diversity at baseline was significantly higher in CD patients who achieved clinical remission at
week 14 compared to those who did not achieve this endpoint. Among responders, two taxa species,
Roseburia inulinivorans and Burkholderiales, were significantly more abundant at baseline than at week
14. No significant association was found between gut microbiota and clinical remission at week 14 in
UC patients [79].
It has been reported that reduced Firmicutes abundance was correlated with a shorter time to
relapse after infliximab withdrawal. The abundance of six clades of bacteria, including Eubacterium
rectale and Bifidobacterium spp., predicted the response to anti-TNF medication in pediatric IBD
patients [80]. We investigated, in a prospective study, the gut microbiota profile before and after
adalimumab therapy, in patients with CD. Considering bacterial phyla, Proteobacteria decreased
significantly in patients in whom therapeutic success was obtained, passing from a value of 15.8% to 6.8%,
while in non-responder patients, their percentage did not change. Considering the Lachnospiraceae
family, in patients with normalization of C reactive protein after six months of adalimumab therapy, it
increased from 16.6% to 23.9% (p = 0.049). We concluded that in patients who respond to adalimumab
therapy, by decreasing inflammation, there is a trend to restore the intestinal eubiosis [81]. Thus, gut
microbiota may provide potential biomarkers for monitoring and predicting IBD treatment outcomes.
Since the discovery of the pivotal role of microbiota in inflammatory diseases, an increasing
number of studies has been performed regarding the efficacy of fecal microbiota transplantation
(FMT) in intestinal and extra-intestinal diseases [82]. In the RCT conducted by Moayyedi et al. [83],
the authors found that early diagnosis of UC might result in better outcomes after FMT. This suggested
a potential window of opportunity for FMT after diagnosis of UC. Accordingly, Paramsothy et al. [84]
reported that less severe grades of endoscopic inflammation may be a potential predictor of FMT
response. Moreover, the increase in Clostridium clusters IV and XVIII and the high microbial diversity
were identified as predictors of FMT response. Conversely, the presence of Fusobacterium spp. and
Sutterella spp. were associated with non-response to FMT.
3.3. An Attempt to a Holistic Vision
Grown in number and activity, the anti-cytokine monoclonals are still the preferred treatment
regimen of most clinicians against IBD. However, these drugs may fail to terminate the disease and
may activate paradoxical immune diseases [85]. This suggests that IBD is part of an autoimmune
disease cluster, sharing intertwined regulatory rules with the other members of the cluster (rheumatism,
psoriasis, multiple sclerosis, and others): the dual action of a monoclonal drug may silence one
pro-inflammatory pathway, while disturbing other protective circuits.
Two pieces of evidence must be added to close the circle of the above statements. Firstly, the
pathophysiology of IBD is extraordinarily active beyond the bowel walls, triggering an array of
inflammatory manifestations that can involve joints, biliary tree, skin, and eyes (the well-known
extraintestinal manifestations of IBD) [86]. Secondly, refinement of molecular biology techniques
has led to the revolutionary demonstration of the involvement of gut microbiome, a universe of 1016
bacterial/fungal/viral species, in IBD. This huge metagenome can produce substrates that elude our
limited immunologic repertoire and can ignite inflammation coping with abrupt diet changes but may
also activate a pro-inflammatory phylum responsible for intestinal or extraintestinal pathology [87,88].
At present, therapies that target molecular pathways do not provide uniform benefits for all
patients. New transformative therapies for autoimmune and inflammatory diseases require greater
molecular understanding of patient subsets and the ability to personalize targeted agents [89]. The
integrated “omics” approach, rendered possible through the analysis of a collection of datasets
(termed “big data”), shows promise in designing IBD patient-tailored diagnosis and therapeutic
opportunities. The factors previously mentioned as associated with IBD, i.e., the environment, the
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genes, the microbiota, and the immune systems, may all be critically important but, given their
individual complexity, a functionally integrated vision may be required. The intricate and reciprocal
interaction among these entities, through the so-called ‘IBD interactome’, results in the emergence
of IBD, or more appropriately the ‘IBD integrome’ [90,91]. In its broadest definition, an interactome
indicates the whole set of molecular interactions in a given cell. Such interactions may regard antigens
(for example proteins) but can also describe sets of indirect interactions among genes [92]. Regarding
IBD, an interactome may also be intended to identify sets of mechanisms that are indispensable
for a disease to be maintained, and, ideally, families of drug molecules capable of targeting those
mechanisms leading to disease termination. As far as the latter is concerned, there is wide availability
of drugs that may not work when applied in a general context, but may target specific pathways, and
are thus awaiting proper patient classifying algorithms to be tested.
Genome-wide associated studies of omics data have revealed modules of disease-associated
genes that have been used to obtain a molecular understanding of disease mechanisms [93]. In
addition to gene level, “exposome” or “environome” analysis complements the genome by providing
a comprehensive description of lifelong exposure history: it could be useful for better delineating the
causes and prevention of human disease [94]. It is expected that although the genome is the blueprint
of an individual, its analysis with that of the other “omes” such as the DNA methylome, transcriptome,
proteome, and metabolome, will further provide a dynamic assessment of the physiology and health
state of an individual (the disease interactome) [95]. Existing drugs, targeting specific biological
pathways identified in the interactome analysis, could be tried first in IBD models, then in clinical
practice thereafter [96]. To better define interactome in IBD, a new strategy should focus on pathways of
inflammation, and integrate data from clinical studies obtained by applying biologic treatments. There
is also an urgent need for bioinformatic tools to analyze and integrate the huge quantity of data derived
from “omics” approach in order to obtain comprehensive molecular pathways for IBD. This approach
could lead to identification of IBD molecular subtypes and correlation with clinical phenotypes, and aid
in the discovery of compounds to finally have better disease control [97]. The future IBD therapeutics
should be developed on the basis of targeting, through a systems biology approach, the central hubs in
the IBD network [98].
4. Conclusions
According to today’s vision, the IBD inflammation is not “simply” a universal, highly conserved
force. In any given patient, inflammation may bear the patient’s personal signature, with the microbiome
mainly imprinting its personal touch. If looked at closely, the microbiome is a “transponder” conveying,
to the inner gut, information from the surrounding environment. Easy to predict, the physiologic
“transponder” [91] will be mostly fed by information on diet, establishing a continuous information axis
between the body tending to stability and the variations outside, that call for inflammation remodeling.
Lingering gut inflammation may thus be conceived as the factor keeping our machinery connected to
“what’s going on out there”. Though important, diet composition may be but a part of the “world
out there”: working times, environment, including an interconnected network of variables such as
feeding rhythm, noise pollution, breaking-in artificial light, and scents/odors, all contribute to the
composite message influencing our sensors daily. The anxiety-depression-inflammation equation may
be a reasonable interpretation key of the above premises [85].
A holistic approach could bear more chance of success than single switch inactivation one at a
time, as pursued until now, for example, with biological drugs.
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